Pathophysiology, Severity, Pattern, and Risk Factors for Carboplatin-induced Emesis

Oncology (Switzerland)

Volumn 53, Issue 1, 1996, Pages 46-50

  du Bois, Andreas ^a   Vach, W ^b   Kiechle, M ^c   Cramer Giraud, U ^a   Meerpohl, H G ^a  

^a St Vincentius Hospital Karlsruhe   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

5 hydroxyindole acetic acid (5 HIAA); Antiemetics; Carboplatin; Nausea; Vomiting

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ONDANSETRON; SEROTONIN; SEROTONIN 3 ANTAGONIST;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; STATISTICAL ANALYSIS; VOMITING;

EID: 0029832954     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227640     Document Type: Article

References (29)

1. Advanced Ovarian Cancer Trialist Group: Chemotherapy in advanced ovarian canccr: An overview of randomized clinical trials, BMJ 1991;303:884-893.
2. Knox RJ, Friedlos F, Lydall DA, Roberts JJ: Mechanism of cytotoxicity of anticancer platinum drugs: Evidence that cis-diamminc-di-chloroplatinum (II) and cis-diammine (1.1-cy-clobutancdicarboxylato) platinum (II) differ only in the kinetics of their interaction with the DNA, Cancer Res 1986;46:1972-1979.
3. Micetich KC, Barnes D, Erickson LC: A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(l, l-cyclo-butancdicarboxylato)-platinum (II) and cis-diammincdichloroplatinum (II) on L 1210 cells, Cancer Res 1985;45:4043-4047.
4. Tcrheggen PMAB, Begg AC, Emondt JY, Dub-belman R, Floot BGJ, den Engelse L: Formation of interaction products of carboplatin with DNA in vitro and in canccr patients, Br J Canccr 1991:63:195-200.
5. Gaver RC, Decb G: High-pcrformancc liquid chromatographic procedure for the analysis of carboplatin in human plasma and urine, Cancer Chcmother Pharmacol 1986; 16:201-206.
6. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR: Pharmacokinetics of cis-diammine-1,1 cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function, Canccr Res 1984:44: 1693-1697.
7. Trump DL, Grem JL, Tutsch KD, Wilson JK, Simon KJ, Alberti D, Storer B, Tormey DC: Platinum analogue combination chemotherapy, Cisplatin and carboplatin: A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion, J Clin Oncol 1987;5:1281-1289.
8. Elfrink F, van der Vijgh WJF, Klein I, Ver-morken JB, Gall HE, Pincdo HM: Pharmacokinetics of carboplatin after iv administration, CancerTreat Rep 1987;71:1231-1237.
9. Schurig JE, Florczyk AP, Bradner WT: Evaluation of platinum complexes for emetic potential, Proc 4th Int Symp Platinum Coordination Complexes, Boston, Mass, 1984, pp 184-199.
10. Adams M, Kerby IJ, Rockcr I, Johansen K, Franks CR: Carboplatin (Paraplatin) clinical trials: Assessment of nausea and vomiting; in I-apis K, Eckhardt S (eds): Anticanccr Drug Research, Basel, Kargcr, 1987, pp 33-44.
11. Gridelli C, Incoronato P, Airoma G, Pcpe R, Arpinelli F, Bianco AR: Ondansetron in the prophylaxis of nausea and vomiting induced by carboplatin combination chemotherapy, Eur J Cancer 1993;29A:651.
12. Smith DB, Rustin GJS, Howells N, Lambert HE, McQuadc B: A phase II study of ondansetron as anticmetic prophylaxis in patients receiving carboplatin for advanced ovarian cancer, Ann Oncol 1991;2:607-608.
13. Harvey VJ, Evans BD, Mitchell PLR, Mak D, Neave LM, Langley GB, Dickson DSP: Reduction of carboplatin induced emesis by ondansetron, Br J Cancer 1991;63:942-944.
14. Du Bois A, Vach W, Thomssen C, Karck U, Madjar H, Mccrpohl HG: Comparison of the emetogenic potential between cisplatin and carboplatin, Acta Oncol 1994;33:531-535.
15. Costall B, Naylor RJ: Neuropharmacology of emesis in relation to clinical response, Br J Cancer 1992;66(suppl 14):2-8.
16. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL: Efficacy of ondansetron (GR 38032F) and the role of scrotoninc in cisplatin-induced nausea and vomiting, N Engl J Med 1990;322:810-816.
17. Du Bois A, Meerpohl HG, Siebert C, Berck JS, Pfleiderer A: Excretion patterns of 5-HIAA under platinum based chemotherapy: The role of 5-HT in drug-induced emesis (abstract 1322), ProcASCO 1992:11:318.
18. Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M, Fomi M: Urinary' serotonin metabolite excretion during cisplatin chemotherapy, Cancer 1993;72:2239-2241.
19. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ: Changes in serotonin metabolism in cancer patients: Its relationship to nausea and vomiting induced by chemotherapy drugs, Br J Cancer 1992;66:198-203.
20. Martin M, Diaz-Rubio E, Sanchez A, Almcna-rcz J, Lopez-Vcga JM: The natural course of emesis after carboplatin treatment, Acta Oncol 1990:29:593-597.
21. De Mulder PHM, Seynacvc C, Vermorken JB, van Licssum PA, Mols-Jevdcvic S, Lane All-man E, Beranek P, Verweij T: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting, Ann Intern Med 1990;113:834-840.
22. Du Bois A, Meerpohl HG, Vach W, Kommoss FGM, Fenzl E, Pfleiderer A: Course, patterns, and risk factors for chemotherapy-induced emesis in cisplatin-prctrcated patients: A study with ondansetron, Eur J Cancer 1992;28:450-457.
23. Pollera CF, Giannarelli D: Prognostic factors influencing cisplatin-induced emesis, Cancer 1989;64:1117-1122.
24. Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, Malacame P, Monici ML, Di Costanzo F, Patoia L, Ballatori E, To-gnoni G, Del Favero A: Protection from nausea and vomiting in cisplatin-treated patients: High-dose mctoclopramide combined with methylprednisolone vs, mctoclopramide combined with dexamethasone and diphenhydramine, J Clin Oncol 1989;7:1693-1700.
25. Sridhar KS, Donnelly E: Combination anti-emetics for cisplatin chemotherapy, Canccr 1988;61:1508-1517.
26. Morrow GR: Chemotherapy-related nausea and vomiting: Etiology and management, CA 1989;39:89-104.
27. Morrow GR: The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy, Cancer 1985:55:2766-2770.
28. Sullivan JR, Leyden MJ: Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion (letter), N Engl J Med 1983: 309:796.
29. Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthovcn J: Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting, Support Care Cancer 1994;2:161-166.